Advertisement

International Journal of Hematology

, Volume 73, Issue 4, pp 496–501 | Cite as

Effect of Additional Chromosomal Abnormalities in Acute Promyelocytic Leukemia Treated With All-trans-Retinoic Acid: A Report of 17 Patients

  • Yasushi Okoshi
  • Hideki Akiyama
  • Natsu Kono
  • Tomoko Matsumura
  • Daisuke Mizuchi
  • Shin-Ichiro Mori
  • Kazuteru Ohashi
  • Hisashi Sakamaki
Rapid Communication

Abstract

Seventeen cases of acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and combination chemotherapy at Tokyo Metropolitan Komagome Hospital between 1992 and 1999 were reviewed, and divided into 2 kary-otype-based cytogenetic groups. One group comprised 7 patients with either the typical t(15;17) alone or a normal karyotype, and the other group comprised 10 patients with additional karyotypic abnormalities. No patient had received prior chemotherapy or irradiation, and no cases were complicated by a history of myelodysplastic syndrome before the diagnosis of APL. There were no significant differences in clinical characteristics at disease presentation. Complete remission was achieved in all 17 patients and karyotypes of bone marrow cells normalized in all cases. No differences were found in relapse rate, overall survival, or disease-free survival between the 2 groups.

The analysis did not reveal any significant effect of additional chromosomal abnormalities on the prognosis of APL patients undergoing treatment with ATRA. However, a small number of patients were assessed in this study, and further cumulative studies are needed.

Key words

Acute promyelocytic leukemia All-trans-retinoic acid Chromosomal abnormality 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Berger R, Le Coniat M, Derre J, Vecchione D, Jonveaux P. Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities.Genes Chromosomes Cancer. 1991;3:332–337.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Schoch C, Haase D, Haferlach T, et al. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients.Br J Haematol. 1996;94:493–500.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Slack JL, Arthur DC, Lawrence D, et al. Secondary cytogenetic changes in acute promyelocytic leukemia—prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a cancer and leukemia group B study.J Clin Oncol. 1997;15:1786–1795.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hiorns LR, Swansbury GJ, Mehta J, et al. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia.Br J Haematol. 1997;96:314–312.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Pandolfi PP, Alcalay M, Fagioli M, et al. Genomic variability and alternative splicing generate multiple PML/RARa transcripts that encode aberrant PML proteins and PML/RARa isoforms in acute promyelocytic leukaemia.EMBO J. 1992;11:1397–1407.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Huang W, Sun GL, Li XS, et al. Acute promyelocytic leukemia: clinical relevance of two major PML-RARa isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse.Blood. 1993;82:1264–1269.Google Scholar
  7. 7.
    Kanamaru A, Takemoto Y, Tanimoto M, et al.All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia.Blood. 1995;85:1202–1206.PubMedGoogle Scholar
  8. 8.
    Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy.Blood. 1997;90:1014–1021.PubMedGoogle Scholar
  9. 9.
    Avvisati G, Coco FL, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) pilot study.Blood. 1996;88:1390–1398.PubMedGoogle Scholar
  10. 10.
    Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia.Blood. 1999;94:1192–1200.PubMedGoogle Scholar
  11. 11.
    Ogawa K, Shineha H, Abe R, et al. Acute promyelocytic leukemia with a history of RAEB in transformation and the 15/17 translocation.Jpn J Clin Hematol. 1989;30:67–71.Google Scholar
  12. 12.
    Dalton, Jr. WT, Cork A, Stass SA, Trujillo JM. Chronic myelomonocytic leukemia with trisomy 8 and related clone with trisomy 8 and t(15;17).Cancer Genet Cytogenet. 1988;32:287–292.CrossRefPubMedGoogle Scholar
  13. 13.
    Detourmignies L, Castaigne S, Stoppa AM, et al. Therapy-related acute promyelocytic leukemia: a roport on 16 cases.J Clin Oncol. 1992;10:1430–1435.CrossRefPubMedGoogle Scholar
  14. 14.
    Bhavnani M, Al Azzawi S, Liu Yin JA, Lucas GS. Therapy-related acute promyelocytic leukaemia.Br J Haematol. 1994;86:231–232.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2001

Authors and Affiliations

  • Yasushi Okoshi
    • 1
  • Hideki Akiyama
    • 1
  • Natsu Kono
    • 1
  • Tomoko Matsumura
    • 1
  • Daisuke Mizuchi
    • 1
  • Shin-Ichiro Mori
    • 1
  • Kazuteru Ohashi
    • 1
  • Hisashi Sakamaki
    • 1
  1. 1.Hematology DivisionTokyo Metropolitan Komagome HospitalTokyoJapan

Personalised recommendations